JP Morgan Private Wealth Advisors’s Matinas BioPharma MTNB Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-634	Closed	-$26K	–	1991
2022 Q1	$26K	Hold	634	–	–	﹤0.01%	1971
2021 Q4	$32K	Hold	634	–	–	﹤0.01%	1961
2021 Q3	$41K	Buy	+634	New	+$27.4K	﹤0.01%	1916
2019 Q3	–	Sell	-600	Closed	-$26K	–	1463
2019 Q2	$26K	Hold	600	–	–	﹤0.01%	1363
2019 Q1	$33K	Hold	600	–	–	﹤0.01%	1443
2018 Q4	$18K	Hold	600	–	–	﹤0.01%	1439
2018 Q3	$28K	Hold	600	–	–	﹤0.01%	1556
2018 Q2	$13K	Hold	600	–	–	﹤0.01%	1457
2018 Q1	$23K	Buy	+600	New	+$31.7K	﹤0.01%	1272
2017 Q4	–	Sell	-600	Closed	-$40K	–	1315
2017 Q3	$40K	Buy	+600	New	+$40K	﹤0.01%	1221

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

JP Morgan Private Wealth Advisors's MTNB Position: Q2 2022 in Review

JP Morgan Private Wealth Advisors sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 634 shares — an estimated $26K sold.

JP Morgan Private Wealth Advisors first reported a position in MTNB in Q3 2017 and held it in 10 quarters. The position peaked at $41K in Q3 2021. 50 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

JP Morgan Private Wealth Advisors reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 634 Matinas BioPharma shares in Q2 2022, an estimated $26K.
JP Morgan Private Wealth Advisors first reported a position in Matinas BioPharma in Q3 2017 and held it in 10 quarters.
JP Morgan Private Wealth Advisors's Matinas BioPharma position peaked at $41K in Q3 2021.
50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.